Nature's Sunshine Names CFO, Posts Q2 Results, and Trims Full-Year Outlook
NATR sits 26% above its 52-week low of $12.973.
Summary
Nature's Sunshine reported Q2 2026 earnings with sales up 2% to $117 million but cut full-year guidance, citing FX headwinds and China softness. The company also named Ruth Perkins as its new CFO, effective September 1.
Key Events · Earnings and Guidance · NATR
-
Full-Year Guidance Lowered
Management cut 2026 net sales guidance to $490-$500 million from $500-$515 million and adjusted EBITDA to $48-$52 million from $50-$54 million, citing a stronger U.S. dollar and recent softness in China.
-
Q2 Earnings Mixed
Net sales rose 2% to $117.0 million (4% constant currency), gross margin expanded 194 bps to 73.7%, but GAAP EPS fell to $0.19 from $0.28 a year ago due to higher SG&A and lower other income.
-
New CFO Appointed
Ruth Perkins, formerly SVP at Estée Lauder, will become EVP and CFO effective September 1, 2026, with a $575,000 base salary, 70% target bonus, and $1.65 million in equity awards. She fills the vacancy left by the prior CFO's resignation in May 2026.
-
Balance Sheet Remains Strong
Cash and equivalents stood at $82.5 million with zero debt as of June 30, 2026, though operating cash flow was negative $1.0 million in the first half of 2026.
Analysis · NATR · Life Sciences
A mixed quarter for Nature's Sunshine: sales edged up 2% to $117 million and gross margins improved, yet GAAP EPS slipped to $0.19 from $0.28 a year ago. The bigger story is management's decision to lower full-year revenue and adjusted EBITDA guidance, pointing to a stronger dollar and softness in China. Effective September 1, Ruth Perkins steps in as CFO, filling the gap left by the prior CFO's May resignation. Her package includes a $575,000 salary, a 70% target bonus, and $1.65 million in equity awards. The guidance cut dominates the narrative—it resets expectations lower and will likely weigh on the stock.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 35.6% of the 1100 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NATR was trading at $16.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $357.7M. The 52-week trading range was $12.97 to $28.14. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.